Belite Bio, Inc. filings document foreign-issuer disclosures for a clinical-stage biopharmaceutical company developing tinlarebant for degenerative retinal diseases. Form 6-K reports furnish press releases on clinical-trial progress, FDA-related regulatory updates, financial results, annual-report availability, material agreements, shareholder matters, and capital-structure activity involving American Depositary Shares.
The company's Form 20-F reporting framework covers audited consolidated financial statements and public-company disclosure for BLTE as a foreign private issuer. Its filing record centers on STGD1, geographic atrophy in advanced dry AMD, tinlarebant development, financing activity, governance matters, and the incorporation of furnished reports into effective Securities Act registration statements.
Belite Bio, Inc. reports a beneficial ownership statement for Yu-Hsin Lin. The filing shows 1,253,935 Ordinary Shares beneficially owned by Mr. Lin, equal to 3.1% of the class. The filing states the company had 40,085,091 Ordinary Shares outstanding as of March 31, 2026.
The notes state Mr. Lin is deemed to hold a total of 2,728,462 Ordinary Shares when including (i) 353,083 shares directly held, (ii) 900,852 shares underlying vested or soon-to-vest options and RSUs, and (iii) 1,474,527 shares held indirectly through Lin BioScience, Inc. Mr. Lin disclaims investment and disposition power over the indirect holdings.
Belite Bio Chief Scientific Officer Nathan L. Mata sold shares of the company in pre-planned trades. On May 7, 2026, he executed four open-market sales totaling 666 American depositary shares at prices ranging from about $152 to $155 per share.
Each American depositary share represents one ordinary share of Belite Bio. The sales were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-scheduled. Following these transactions, Mata reported no American depositary shares held directly and no remaining derivative positions in this filing.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares (ADS) of BELITE BIO, INC in multiple open-market transactions. The sales occurred on May 6, 2026 at prices ranging from about $151.57 to $156.00 per ADS. Each ADS represents one ordinary share of the company. The filing notes that these transactions were made under a Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were pre-arranged rather than timed discretionarily.
Belite Bio, Inc. Chief Scientific Officer Nathan L. Mata reported open-market sales of 1,000 American depositary shares (ADSs) on May 5, 2026. The ADSs were sold in multiple trades at prices ranging from about $153.92 to $158.11.
The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating they were scheduled in advance. Following the transactions, Mata directly holds 2,546 ADSs of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata executed pre-planned open-market sales of 1,000 American depositary shares. On May 4, 2026, he sold ADS in multiple trades between weighted average prices of about $153 and $158, as detailed in the filing.
The sales were carried out under a Rule 10b5-1 trading plan that Mata adopted on December 10, 2025, indicating they were scheduled in advance rather than timed discretionarily. Following these transactions, he directly holds 3,634 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata reported open-market sales of company stock. On May 1, 2026, he sold a total of 1,000 American depositary shares (ADS), with each ADS representing one ordinary share of Belite Bio.
The sales were executed in multiple trades at prices ranging from about $153.8 to $160 per ADS and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. The filing does not show any option exercises or derivative transactions alongside these sales.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares of the company in open-market transactions. The sales occurred on April 30, 2026 at weighted average prices reported between $155.62 and $158.42 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sales, Mata directly holds 4,666 American depositary shares of Belite Bio, Inc.
Belite Bio Chief Scientific Officer Nathan L. Mata sold a total of 1,000 American depositary shares in open-market transactions on April 29, 2026. The sales occurred at weighted average prices ranging from about $154.22 to $158.21, according to the filing footnotes.
The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. After these sales, Mata directly holds 5,666 ADS of Belite Bio.
Belite Bio Chief Scientific Officer Nathan L. Mata sold 1,000 American depositary shares (ADS) of BELITE BIO, INC in open-market transactions on April 28, 2026. The ADS were sold in multiple small trades at weighted average prices ranging from $154.62 to $162.59 per ADS.
The sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on December 10, 2025, indicating they were scheduled in advance. Following these transactions, he directly owned 7,654 ADS of the company.
Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.